SAA2 and early-onset autosomal dominant Alzheimer disease: Non-glycosylated A-SAA has been identified as being locally expressed in normal tissue cells, tumor cells, chronic obstructive pulmonary disease, rheumatoid synovial tissues, atherosclerotic plaques, and neuroinflammatory lesions in the brains of Alzheimer’s disease patients.